RJA
ENZ

Raymond James & Associates’s Enzo Biochem, Inc. ENZ Stock Holding History

Raymond James & Associates’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,058
Closed -$60K – 4296
2021
Q3 		$60K Buy
+17,058
New +$56.9K ﹤0.01% 3897

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCA
VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's ENZ Position: Q4 2021 in Review

Raymond James & Associates sold out of Enzo Biochem, Inc. (ENZ) in Q4 2021, closing a stake of 17,058 shares — an estimated $60K sold.

Raymond James & Associates first reported a position in ENZ in Q3 2021 and held it in 1 quarter. The position peaked at $60K in Q3 2021. 59 funds tracked by Wall St. Rank hold ENZ as of Q4 2021.

  • Raymond James & Associates reported no remaining Enzo Biochem, Inc. position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 17,058 Enzo Biochem, Inc. shares in Q4 2021, an estimated $60K.
  • Raymond James & Associates first reported a position in Enzo Biochem, Inc. in Q3 2021 and held it in 1 quarter.
  • Raymond James & Associates's Enzo Biochem, Inc. position peaked at $60K in Q3 2021.
  • 59 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.